Longstanding concerns about Iran's dual-use biotechnology sector and possible offensive biological research have surfaced again in recent commentary. One widely circulated piece asks a pointed question: if reports from more than two decades ago already pointed to Iranian interest in weaponising highly dangerous pathogens, including smallpox, how far might any such effort have advanced by now? The question is speculative, but it sits against a backdrop of consistent U.S. government assessments that Iran has not abandoned the intention to pursue research and development of biological agents and toxins for offensive purposes. Those assessments emphasize flexibility within legitimate public-health and biodefense work that could, on leadership decision, be redirected toward lethal capability. Official language has grown more pointed in recent years, with some intelligence summaries describing Iran as "very likely" continuing relevant R&D.
Iran is a party to the Biological Weapons Convention and has publicly renounced biological weapons. At the same time, its extensive network of universities, research institutes, pharmaceutical facilities, and entities linked to the Islamic Revolutionary Guard Corps creates inherent dual-use potential. Western compliance reports have repeatedly flagged lack of transparency and activities that raise Article I concerns under the treaty. Opposition groups have long alleged specific agent work; those claims are difficult to verify independently and must be treated with caution. No open-source evidence confirms an active, ready-to-use stockpile of weaponised smallpox or comparable agents. Official smallpox (Variola) stocks are supposed to exist only in two high-containment repositories. Allegations that other countries retained samples have circulated for years without definitive public confirmation regarding Iran.
Still, the worst-case logic is straightforward and severe. Biological weapons differ from conventional or even chemical arms in their potential for delayed, self-propagating harm, psychological shock, and difficulty of attribution. In a high-intensity regional conflict or as a tool of asymmetric retaliation, a state facing existential pressure might calculate that biological options offer ways to impose costs without immediate, traceable missile or drone signatures. Proxies or covert networks could theoretically be used to complicate response. An eradicated disease such as smallpox would be especially destabilising if ever involved: global vaccination largely ended decades ago, residual population immunity is low, and modern medical systems have little recent clinical experience. Even a limited release could generate outsized panic, strain hospitals, disrupt trade and travel, and force difficult decisions about quarantine, vaccination campaigns, and international cooperation.
Other plausible worst-case pathways include accidental release from dual-use facilities during conflict or internal instability, transfer of materials or expertise to non-state actors, or the use of incapacitating or novel agents that blur the line between warfare and terrorism. Attribution would be slow and contested; response would require rapid international coordination that history shows is often imperfect. Economic and social effects could cascade far beyond the initial casualties, supply-chain interruptions, loss of confidence in public institutions, and pressure for escalatory military or sanctions responses.
These scenarios are constrained by real barriers. Effective biological weapons are technically demanding. Delivery that produces mass effect is harder than popular imagination suggests. Blowback risk to the user or its own population is significant. International isolation and potential military retaliation would follow confirmed use. Iran's leadership has historically preferred other tools of power projection, missiles, proxies, cyber operations, over actions that would invite overwhelming conventional response. The absence of confirmed advanced weaponised programs in open assessments suggests that any capability, if it exists, remains limited or latent rather than operationally mature.
The prudent stance is neither dismissal nor panic. Dual-use biotechnology is expanding worldwide; Iran is not unique in possessing the scientific base that could support misuse. Persistent official concern, combined with the regime's record of opacity and regional adventurism, justifies sustained intelligence focus, strengthened verification under the Biological Weapons Convention, investment in detection and medical countermeasures, and careful planning for securing relevant materials in any future crisis. Historical allegations about pathogens such as smallpox underscore how catastrophic the outer edge of the threat could be. They do not prove that edge has been reached. Yet.
https://michaeltsnyder.substack.com/p/if-iran-was-weaponizing-smallpox